Ana Herranz-Alonso

Ana Herranz-Alonso

Auto-generated profile, based on publicly available information

Ana Herranz-Alonso

Pharmacy Department-CEIMI, Hospital General Universitario Gregorio Marañón, Madrid, Spain

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 August 2020 in Journal of Medical Internet Research
Verified
Journal Article
Open access
RCRoberto Collado-Borrell
Roberto Collado-Borrell
VEVicente Escudero-Vilaplana
Vicente Escudero-Vilaplana
CVCristina Villanueva-Bueno
Cristina Villanueva-Bueno
AHAna Herranz-Alonso
Ana Herranz-Alonso
MSMaria Sanjurjo-Saez
Maria Sanjurjo-Saez
Background: Knowledge of the quantity and quality of apps related to coronavirus disease (COVID-19) is lacking. In addition, no directory has been established listing all the apps developed to address the COVID-19 pandemic. Objective: The aim of this study was to identify smartphone apps designed to address the COVID-19 pandemic and to analyze their characteristics. Methods: We performed an observational, cross-sectional, descriptive study of all smartphone apps associated with COVID-19. Between April 27 and May 2, 2020, we searched the App Store (iOS) and Google Play Store (Android) for COVID-19 apps. The search terms used were coronavirus, COVID-19, and SARS-COV-2. The apps were downloaded and evaluated. The variables analyzed were name, platform, country, language, category, cost, update date, size, version, number of downloads, developer, and purpose. Purpose was further classified into the following categories: news, general information, self-diagnosis, contact tracing, notices to contacts, notification of close cases, awareness, helplines, monitoring of clinical parameters, recording of symptoms and treatment, and messaging with health care professionals. Results: We identified 114 apps on the investigated platforms. Of these, 62/114 (54.4%) were on Android and 52/114 (45.6%) were on iOS. Of the 114 apps, 37 (32.5%) were developed in Europe, 32 (28.1%) in Asia, and 30 (26.3%) in North America. The most frequent languages were English (65/114, 57.0%), Spanish (34/114, 29.8%), and Chinese (14/114, 12.3%). The most common categories were health and well-being/fitness apps (41/114, 41.2%) and medicine apps (43/114, 37.7%). Of the 114 apps, 113 (99.1%) were free. The mean time between the date of the analysis and the date of the last update was 11.1 days (SD 11.0). Overall, 95 of the 114 apps (83.3%) were intended for the general population, 99 apps (7.9%) were intended for health professionals, and 3 apps (2.6%) were intended for both. Regarding the type of developer, 64/114 apps (56.1%) were developed by governments; 42/114 (64.1%) were developed by national governments, and 23/114 (35.9%) were developed by regional governments. The apps with the highest number of downloads (100,000+) were developed by governments (P=.13), except for the World Health Organization app (500,000+). The purposes of the apps available in Western languages (107/114, 93.9%) were determined; the most common purposes were general information about COVID-19 (66, 64.0%), COVID-19 news (53, 51.0%), recording of symptoms (53, 51.0%), and contact tracing (51, 47.7%). More than one purpose was identified for 99/107 apps (92.5%). Conclusions: This paper offers a comprehensive and unique review of all available COVID-19 apps. Governments have adopted these tools during the pandemic, and more than half of the apps were developed by government agencies. The most common purposes of the apps are providing information on the numbers of infected, recovered, and deceased patients, recording of symptoms, and contact tracing.

29 December 2015 in International Journal of Clinical Pharmacy
Verified
Journal Article
Closed access
PDF file
ARAlmudena Ribed
Almudena Ribed
RRRosa María Romero-Jiménez
Rosa María Romero-Jiménez
VEVicente Escudero-Vilaplana
Vicente Escudero-Vilaplana
IIIrene Iglesias-Peinado
Irene Iglesias-Peinado
AHAna Herranz-Alonso
Ana Herranz-Alonso
MSMaria Sanjurjo-Sáez
Maria Sanjurjo-Sáez

1 January 2012 in Journal of the American Medical Informatics Association
Verified
Journal Article
Open access
PDF file
CRCarmen Guadalupe Rodriguez-Gonzalez
Carmen Guadalupe Rodriguez-Gonzalez
AHAna Herranz-Alonso
Ana Herranz-Alonso
MMMaria Luisa Martin-Barbero
Maria Luisa Martin-Barbero
EDEsther Duran-Garcia
Esther Duran-Garcia
MDMaria Isabel Durango-Limarquez
Maria Isabel Durango-Limarquez
MSMaria Sanjurjo-Saez
Maria Sanjurjo-Saez
Objective To identify the frequency of medication administration errors and their potential risk factors in units using a computerized prescription or

23 July 2020 in JMIR mHealth and uHealth
Verified
Journal Article
Open access
MGMiguel Ángel Amor García
Miguel Ángel Amor García
RCRoberto Collado-Borrell
Roberto Collado-Borrell
VEVicente Escudero-Vilaplana
Vicente Escudero-Vilaplana
AOAlejandra Melgarejo Ortuño
Alejandra Melgarejo Ortuño
AHAna Herranz-Alonso
Ana Herranz-Alonso
MSMaría Sanjurjo-Sáez
María Sanjurjo-Sáez
Background: The large number of available cancer apps and their impact on the population necessitates a transparent, objective, and comprehensive evaluation by app experts, health care professionals, and users. To date, there have been no analyses or classifications of apps for patients with genitourinary cancers, which are among the most prevalent types of cancer. Objective: The objective of our study was to analyze the quality of apps for patients diagnosed with genitourinary cancers using the Mobile Application Rating Scale (MARS) and identify high-quality apps. Methods: We performed an observational cross-sectional descriptive study of all smartphone apps for patients diagnosed with genitourinary cancers available on iOS and Android platforms. In July 2019, we searched for all available apps for patients with genitourinary cancers (bladder, prostate, cervical, uterine, endometrial, kidney, testicular, and vulvar) or their caregivers. Apps were downloaded and evaluated, and the general characteristics were entered into a database. The evaluation was performed by 2 independent researchers using the MARS questionnaire, which rates 23 evaluation criteria clustered in 5 domains (Engagement, Functionality, Esthetics, Information, and Subjective Quality) on a scale from 1 to 5. Results: In total, 46 apps were analyzed. Of these, 31 (67%) were available on Android, 6 (13%) on iOS, and 9 (20%) on both platforms. The apps were free in 89% of cases (41/46), and 61% (28/46) had been updated in the previous year. The apps were intended for prostate cancer in 30% of cases (14/46) and cervical cancer in 17% (8/46). The apps were mainly informative (63%, 29/46), preventive (24%, 11/46), and diagnostic (13%, 6/46). Only 7/46 apps (15%) were developed by health care organizations. The mean MARS score for the overall quality of the 46 apps was 2.98 (SD 0.77), with a maximum of 4.63 and a minimum of 1.95. Functionality scores were quite similar for most of the apps, with the greatest differences in Engagement and Esthetics, which showed acceptable scores in one-third of the apps. The 5 apps with the highest MARS score were the following: “Bladder cancer manager,” “Kidney cancer manager,” “My prostate cancer manager,” “Target Ovarian Cancer Symptoms Diary,” and “My Cancer Coach.” We observed statistically significant differences in the MARS score between the operating systems and the developer types (P<.001 and P=.01, respectively), but not for cost (P=.62). Conclusions: MARS is a helpful methodology to decide which apps can be prescribed to patients and to identify which features should be addressed to improve these tools. Most of the apps designed for patients with genitourinary cancers only try to provide data about the disease, without coherent interactivity. The participation of health professionals in the development of these apps is low; nevertheless, we observed that both the participation of health professionals and regular updates were correlated with quality.

1 December 2012 in European Journal of Internal Medicine
Verified
Journal Article
Closed access
AZAna Clara Zoni
Ana Clara Zoni
MGMaría Esther Durán García
María Esther Durán García
AMAna Belén Jiménez Muñoz
Ana Belén Jiménez Muñoz
RPRoberto Salomón Pérez
Roberto Salomón Pérez
PMPaloma Martin
Paloma Martin
AAAna Herranz Alonso
Ana Herranz Alonso

1 January 2016
Verified
Journal Article
Closed access
RCRoberto Collado-Borrell
Roberto Collado-Borrell
VEVicente Escudero-Vilaplana
Vicente Escudero-Vilaplana
ARAlmudena Ribed-Sánchez
Almudena Ribed-Sánchez
SISara Ibañez-García
Sara Ibañez-García
AHAna Herranz-Alonso
Ana Herranz-Alonso
MSMaría Sanjurjo-Sáez
María Sanjurjo-Sáez